|
|
|
|
Vol. 61, Issue 4, 710-719, April 2002
The Pediatric Center for Neuroscience, Children's Hospital of
Pittsburgh, Pittsburgh, Pennsylvania (C.Y., Y.L., K.D.N., J.W., R.M.R.,
N.F.S.); and Department of Pharmacology and Therapeutics, McGill
University Cancer Center, Montreal, Quebec, Canada (H.U.S.)
Growth factors, including nerve growth factor (NGF), have been
hypothesized to play a role in resistance to chemotherapeutic agent-induced apoptosis. Induction by NGF of resistance to apoptosis is
primarily thought to be the result of its binding to its high-affinity receptor, TrkA. The low-affinity NGF receptor, p75, has long been thought merely to facilitate NGF binding to TrkA. However, we have
previously shown that the binding of NGF to its low-affinity receptor,
p75, protects neuroblastoma cells that do not express TrkA against
apoptosis induced by enediyne chemotherapeutic agents. In cells that
express both receptors, it is not clear what determines which receptor
is responsible for the protective effect of NGF. We now show that, in
enediyne-treated SH-SY5Y neuroblastoma transfectants with native levels
of p75 and a low TrkA/p75 ratio (1/100), the anti-apoptotic effect of
NGF requires binding to p75. In contrast, in transfectants with native
levels of p75 and a high TrkA/p75 ratio (100/100), NGF treatment
prevents enediyne-induced apoptosis by a mechanism independent of p75
binding. Treatment of low TrkA/p75 ratio cells with NGF results in
activation and nuclear translocation of NF-
B and tyrosine
phosphorylation of TrkA. Analogous treatment of high TrkA/p75 ratio
cells results only in phosphorylation of TrkA even though nuclear
factor (NF)-
B signaling is not inactive and can be initiated by
other ligands. The ratio of TrkA/p75 in cells that express both
receptors probably contributes to the determination of which of the two
known roles of p75 (i.e., TrkA independent or TrkA facilitatory) are
responsible for NGF-mediated protection from enediyne-induced apoptosis.